# Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

> **NCT04750239** · PHASE1,PHASE2 · TERMINATED · sponsor: **Y-mAbs Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- SCLC

## Interventions

- **DRUG:** Nivatrotamab

## Key facts

- **NCT ID:** NCT04750239
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-17
- **Primary completion:** 2022-04-08
- **Final completion:** 2022-04-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated due to business priorities
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04750239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04750239, "Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04750239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*